HemaCare scientists have just published a white paper on a new raw material sourcing paradigm that they hope will transform the industry.
The publication centers on dedicated donors; recallable donors who are reserved to specific research programs. The basic premise is that clients will be able to reserve self-identified recallable donors who possess physiological or demographic traits deemed beneficial to a particular research program.
New webinar highlights the benefits of “dedicated donor pools” - the latest offering from HemaCare to accelerate successful cell therapy research and commercialization
HemaCare, through Charles River Labs, recently hosted an educational webinar focused on their latest cell and gene therapy-related service.
HemaCare will now be working with clients to establish “dedicated donor” pools. The purpose of this new program is to establish and maintain a pool of reliable, recallable donors with client-determined physiological and/or demographic characteristics that match specific client research projects and programs.
HemaCare is pleased to announce the publication of their latest article [1] in the current issue of BioProcess International.
The piece, entitled “The Cell Therapy Industry Needs High-Quality Healthy-Donor Material”, gives readers expert insight into the growing demand for cell therapy starting material, and how that demand is impacting suppliers.
Scientists at the Cell and Gene Therapy Catapult in the U.K. cite using HemaCare leukopaks to study a new method of scrutinizing cellular quality markers during cell therapy bioprocessing. [1]
The publication represents a collaborative effort among scientists developing cellular therapies in the United States and Canada as well as in the U.K. They are working together to solve a key issue; how to ensure the consistent high quality of their living products.
Last week in Part 1 of our series, we presented observations from industry leaders into how they plan for success by installing comprehensive quality management systems and laying down detailed groundwork for an optimized transition to GMP-compliant starting materials and technologies. This week in Part 2 of our series, cell therapy manufacturers present their own perceptions of what constitutes an ideal cell therapy starting material supplier, as well as what can be done on their end to ensure their cell therapy retains consistent quality and potency.